INmune Bio Inc (INMB)

INmune Bio Inc (INMB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $53.6M; returns 1 day -5.2%, 1 week -7.0%, 1 year -18.4%.

INmune Bio Inc. (INMB) is a clinical-stage biotechnology company focused on developing therapies that modulate the innate immune system to combat serious diseases. The company currently has three primary clinical-stage platforms: DN-TNF (XPro™), CORDStrom™, and INKmune™.

Groups INMB belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Immunotherapy
• Alzheimer's Disease
• Neuroscience
• Oncology
• CNS Disorders
• Rare Diseases
• Life Sciences

INMB financial model: income statement, cash flow and balance sheet